High
5.0853
Open
4.700
VWAP
4.99
Vol
4.60K
Mkt Cap
18.33M
Low
4.700
Amount
22.95K
EV/EBITDA(TTM)
--
Total Shares
3.65M
EV
11.16M
EV/OCF(TTM)
--
P/S(TTM)
47.11
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
FY2023Q3
1.77M
+3.69%
--
--
1.86M
-0.53%
--
--
Estimates Revision
Stock Price
Go Down
-23.02%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Pulmatrix Inc (PULM.O) is -0.94, compared to its 5-year average forward P/E of -1.21. For a more detailed relative valuation and DCF analysis to assess Pulmatrix Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.21
Current PE
-0.94
Overvalued PE
-0.31
Undervalued PE
-2.12
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.79
Current PS
2.61
Overvalued PS
12.46
Undervalued PS
-0.89
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
-52.85%
-1.55M
Operating Profit
FY2025Q2
YoY :
-73.34%
-1.55M
Net Income after Tax
FY2025Q2
YoY :
-73.58%
-0.42
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PULM News & Events
Events Timeline
2025-08-06 (ET)
2025-08-06
08:12:23
Pulmatrix to potentially divest its patent portfolio for iSPERSE technology
Sign Up For More Events
Sign Up For More Events
News
9.5
08-07NASDAQ.COMPulmatrix (PULM) Q2 Revenue Falls 100%
9.5
08-06PRnewswirePulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
9.5
05-15NewsfilterPulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
Sign Up For More News
People Also Watch
CETY
Clean Energy Technologies Inc
0.245
USD
+3.81%
FEDU
Four Seasons Education (Cayman) Inc
15.950
USD
0.00%
GLXG
Galaxy Payroll Group Ltd
0.513
USD
-8.07%
RCON
Recon Technology Ltd
2.690
USD
-4.95%
IHT
InnSuites Hospitality Trust
1.970
USD
-3.43%
KAPA
Kairos Pharma Ltd
1.240
USD
+15.89%
NXTC
NextCure Inc
5.148
USD
-0.81%
GDC
GD Culture Group Ltd
2.900
USD
-3.33%
DATS
Myseum Inc
0
USD
+13.75%
FAQ
What is Pulmatrix Inc (PULM) stock price today?
The current price of PULM is 5.02 USD — it has increased 7.96 % in the last trading day.
What is Pulmatrix Inc (PULM)'s business?
What is the price predicton of PULM Stock?
What is Pulmatrix Inc (PULM)'s revenue for the last quarter?
What is Pulmatrix Inc (PULM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Pulmatrix Inc (PULM)'s fundamentals?
How many employees does Pulmatrix Inc (PULM). have?